Platelet-active drugs in the secondary prevention of cardiovascular events: an overview.
Experimental and clinical evidence strongly suggests that platelets play an important role in a variety of acute cardiovascular events, as well as in the vascular disease with which they are frequently associated. Hence, there is considerable interest in the use of platelet-active drugs in the prevention of these events. A sound pharmacologic basis for the use of platelet-active agents will require further advances in our understanding of the pathophysiology of cardiovascular events and the pharmacology of these drugs.
D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000503:physiopathology; D003327:Coronary Disease / Q000188:drug therapy; D004176:Dipyridamole / Q000627:therapeutic use; D013442:Sulfinpyrazone / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy
D004176:Dipyridamole; D001241:Aspirin; D013442:Sulfinpyrazone